Trump Wants to Be the Hero Vapers Don’t Really Need

The latest move by President Donald Trump to win favor with vapers and the vaping industry has left many perplexed. Just last month, his FDA authorized the sale of blueberry- and mango-flavored vape juices made by Glas, a company that had previously failed to gain approval for its products. This decision was seen as the final straw by recently departed FDA commissioner Marty Makary, who expressed concern about the appeal of these products to children.

The shift in policy is attributed in part to Trump’s 2020 election woes, when he faced opposition from vapers and vape shop owners in key swing states. Mitch Zeller, a former FDA official, noted that Trump “immediately backpedaled” on plans to rein in the vaping industry after facing disapproval from this group.

Trump’s decision to court vapers appears to be a ploy to win over a fringe demographic that may not sway election results but could provide valuable publicity. Vaping is still a relatively small habit, with only 7% of adults in the US using e-cigarettes, according to CDC data from 2024.

A more concerning aspect of this situation is the cozy relationship between Trump and the tobacco industry. Reynolds American, a subsidiary of which contributed millions of dollars to Make America Great Again Inc PAC in 2024, has reportedly helped finance Trump’s ballroom plans. This raises questions about whether Trump prioritizes the interests of big tobacco over public health concerns.

The FDA’s decision to authorize flavored vapes may have been influenced by public opinion on this issue, but it also reflects a broader trend of the administration yielding to special interests. Trump has promised to “save vaping” and has been sympathetic to other vice-adjacent industries, including psychedelics and prediction markets.

In an era where science is increasingly politicized, the FDA’s decision raises more questions than answers. What does this mean for public health? Will Trump’s FDA continue to prioritize industry interests over evidence-based policy?

The stakes are high as the vaping epidemic continues to claim lives, particularly among young people. According to a 2024 estimate, more than 80% of e-cigarettes on the US market were sold illegally because they don’t have FDA authorization.

As Trump courts vapers and big tobacco, it’s essential to remember that this is not just about public health; it’s also about corporate interests and their influence on policy. The long-term consequences of these decisions are far from clear, but one thing is certain: the vaping industry will continue to thrive in the absence of a strong crackdown from the FDA.

In reality, Trump’s decision may be seen as a desperate attempt to placate a small demographic, but it also reflects a deeper problem with his administration: its willingness to prioritize corporate interests over public health concerns. As we watch this drama unfold, one thing is clear: the stakes are high, and the future of public health hangs in the balance.

The decision to authorize flavored vapes may lead to a surge in vaping among adults, potentially undermining efforts to reduce smoking rates. Alternatively, it could drive more business towards unregulated e-cigarettes pouring into the country from China. The long-term consequences of this decision are uncertain.

The relationship between Trump and big tobacco is far from new, but what’s striking is how openly this has been displayed in recent years. Big tobacco companies have dumped millions of dollars into Make America Great Again Inc PAC, raising questions about whether Trump prioritizes the interests of big tobacco over public health concerns.

The FDA’s decision to authorize flavored vapes may have been influenced by science, but it also reflects a broader trend of the administration yielding to special interests. What does this mean for public health? Will Trump’s FDA continue to prioritize industry interests over evidence-based policy?

The vaping epidemic continues to claim lives, particularly among young people. According to a 2024 estimate, more than 80% of e-cigarettes on the US market were sold illegally because they don’t have FDA authorization. What does this mean for public health? Will Trump’s FDA continue to prioritize industry interests over evidence-based policy?

As we watch this drama unfold, one thing is clear: the stakes are high, and the future of public health hangs in the balance. Trump’s decision may be seen as a desperate attempt to placate a small demographic, but it also reflects a deeper problem with his administration: its willingness to prioritize corporate interests over public health concerns.

The final straw has been laid down, and now it’s time for accountability. Will Trump’s FDA continue to prioritize industry interests over evidence-based policy? Or will it take steps to address the vaping epidemic and protect public health? Only time will tell.